 |
Vol.61 No.2 contents | Japanese/English |
 | Full Text of PDF (360K) Article in Japanese |
- Original Article -
A Real-world Survey on Re-biopsies in Patients with Lung Cancer in Chiba Prefecture
Yuki Ito1, Yuki Sata1, Takahiro Nakajima1, Hironori Ashinuma2, Masato Shingyoji2, Haruhisa Saito3, Tsukasa Ishiwata4, Jiro Terada4, Shunichiro Iwasawa5, Ayumu Otsuki6, Masafumi Misawa6, Gaku Yamaguchi7, Chimori Konaka7, Taiki Fujiwara8, Tomohiko Iida8, Fuminobu Kuroda9, Ichiro Yoshino11Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Japan, 2Division of Respirology, Chiba Cancer Center, Japan, 3Department of Respiratory Medicine, Asahi General Hospital, Japan, 4Department of Respirology, 5Department of Advancing Research on Treatment Strategies for Respiratory Disease, Chiba University Graduate School of Medicine, Japan, 6Department of Pulmonology, Kameda Medical Center, Japan, 7Department of Thoracic Surgery, International University of Health and Welfare Ichikawa Hospital, Japan, 8Department of Thoracic Surgery, Kimitsu Chuo Hospital, Japan, 9Department of Respiratory Medicine, Chibaken Saiseikai Narashino Hospital, Japan
Background. To clarify the current status of re-biopsies for lung cancer in daily clinical practice, we conducted a multicenter prospective observational registry study in Chiba prefecture. Method. Between September 2017 and March 2019, we prospectively enrolled 73 patients who underwent a re-biopsy as a second biopsy during treatment for primary lung cancer at 7 registered centers in Chiba Prefecture and analyzed the clinicopathological characteristics of the patients. Results. The biopsy sites were 39 lungs, 21 regional lymph nodes, 4 bones, 3 pleural effusion samples, 3 livers, and 1 each of the brain, skin, and axillary lymph node. The biopsy modalities were 55 bronchoscopies, 12 percutaneous needle biopsies, 4 surgical biopsies and 2 computed tomography-guided biopsies. A pathological diagnosis was possible in 87.6% (64/73 biopsies). Driver gene mutation re-assessment was successfully performed in 98.2% (55/56 biopsies, only for adenocarcinoma). Among the molecular target therapy-resistant cases, T790M was detected in 47.7% (21/44 biopsies), and histological transformation was observed in 8.6% (5/58 cases). The Tumor Proportion Score (TPS) was assessed for 32 patients, and the TPS was 0% in 37.5%, 1-49% in 34.4%, and ≥50% in 28.1%. Conclusion. This consortium, which was formed through the cooperation of multiple departments at multiple centers, revealed the current status of re-biopsies for lung cancer in Chiba Prefecture. We believe that re-biopsies will continue to play an important role in determining treatment policies for lung cancer.
key words: Lung cancer, Re-biopsy, Driver gene mutation, Resistance, Immunotherapy
Received: July 17, 2020
Accepted: December 1, 2020
JJLC 61 (2): 100-108, 2021
